Not reported

Lead poisoning

Body as a whole- Pain at site of injection, malaise, fatigue, myalgia, arthalgia

Cardiovascular- hypotension, cardiac rhythm irregularites,

CNS- tremors, headache, numbness,tingling.

GI- Cheilosis, nausea, vomting, anorexia, excessive thirst.

GU- Glycosuria,proteinuria, microscopic hematuria and large eoithetlial cells in urinary sediment

Hematologic- transcient bone marrow depressin, anemia

Hypersentivity- histamine-like reactions (sneezing, nasal congestion, lacrimation)

Metabolic- zinc deficiency, hypercalcemia

Renal- acute necrosis ofproximal tubules which may result in fatal nephrosis

Lab test abnormalities- increasing AST, ALT
 

Anuria

Special precautions:
Hydration-avoid excess fliuds in patients with lead encephalopathy and increased intracranial
pressure

Hydration- avoid excess fluidin patients with lead encephalopathy and increased intracranial pressure.
Acutely ill patients may be dehydrated from vomiting. Since EDTA is excreted in the urine establish
urine flow by IV infusion nbefore administring the first dose. Once urine flow is established restrict IV
fluid to basal water and electrolyte requirements.

Warnings-
Do not exceed recomended dosage- EDTA can produce toxic and potentially fatal effects. In lead
enchopathy avoid rapid infusion, the IM route is preferred.

Renal effects- severe acute lead poisioning may cause proteinuria and microscopic hematuria.
EDTA may produce the same signs of renal damage. Perform urineanalysis daily during therapy
 to monitor progression of renal tubular damage.
Perform periodic BUN detreminations before and during each course of therapy.

Heaptic effects- mild increases in ALT and AST are common but return to normal within 48 hours
 of discontinuation of therapy.

Prergnancy- do not use during pregnancy unless potentail benefits outweigh potentail hazards to the
 fetus.

Indications:
Lead poisoning

Dosage:
Effective IV, Sc or IM. IM routes is recommended inpatients with overt or incipent lead
encephalopathy.
 

Pharmacology:
The calcium in edate calcium disodium is readily displaced by heavy metals, such as lead, to
form stable complexes which are excreted in the urine.

Pharmacokinetics:
Edeate calcium disodium is poorly absorbed from the GI tract. The elimination half-life of the
injection is 20 to 60 minutes. About 50% is excreted in the urine in 1 hr, 95% in 24 hrs.
 

Pregnancy:

Do not use during pregnanacy unless the potential benefits outweighs the potential risks to the
fetus.